NCT06559059 is a clinical trial in Lung Cancer Diagnosis, sponsored by NYU Langone Health.

Who is sponsoring NCT06559059?

NCT06559059 is sponsored by NYU Langone Health.

What condition does NCT06559059 study?

NCT06559059 studies Lung Cancer Diagnosis, Colorectal Cancer (Diagnosis), Prostate Cancer Diagnosis, Breast Cancer Diagnosis.

Is NCT06559059 still recruiting?

NCT06559059 is currently recruiting now. Last updated 30 March 2026.

Last reviewed 2026-03-30 · How we verify

NCT06559059

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluating the Implementation of a Comprehensive Multilevel Virtual Oncology Program Among Veterans Diagnosed With Lung, Colorectal, Prostate, and Breast Cancers in the US Department of Veterans Affairs

Recruiting now Last updated 30 March 2026

What this trial tests

trial in Lung Cancer Diagnosis in 1,800 participants. Currently enrolling.

Timeline

18 June 2024

Primary endpoint
31 May 2027

31 July 2027

Quick facts

Lead sponsor	NYU Langone Health
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	1,800
Start date	18 June 2024
Primary completion	31 May 2027
Estimated completion	31 July 2027
Sites	5 locations across United States

Conditions studied

Lung Cancer Diagnosis — all drugs for Lung Cancer Diagnosis →
Colorectal Cancer (Diagnosis) — all drugs for Colorectal Cancer (Diagnosis) →
Prostate Cancer Diagnosis — all drugs for Prostate Cancer Diagnosis →
Breast Cancer Diagnosis — all drugs for Breast Cancer Diagnosis →

Sponsor

NYU Langone Health — full company profile →

Who can join

18 and older, any sex, with Lung Cancer Diagnosis or Colorectal Cancer (Diagnosis). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of the pragmatic trial to test the effectiveness of an existing, ongoing clinical service, the VA National TeleOncology program (NTO), a multilevel telehealth population health management program. The primary aims are to study the intervention and determine its effectiveness on telehealth engagement, clinical quality, and healthcare cost outcomes across personal characteristics.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Lung Cancer Diagnosis

Currently open trials in the same condition.

NCT06122077 — Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening · recruiting

Other NYU Langone Health trials

Trials by the same sponsor.

NCT07214519 — Permanent Supportive Housing Overdose Prevention-2 Study · NA · not yet recruiting
NCT05558267 — Potassium Containing Salt-Substitute in Hemodialysis-Dependent End Stage Kidney Disease · NA · not yet recruiting
NCT06637852 — Sexual and Urinary Function Improvement for Cancer Survivors · NA · not yet recruiting
NCT06236087 — Overdose Prevention Centers and Behavioral Health · not yet recruiting
NCT06462027 — Packed Red Blood Cell Transfusion During Cardiac Arrest · Phase 1 · suspended

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06559059 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by NYU Langone Health
Last refreshed: 30 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06559059.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing